Historical Valuation
Foghorn Therapeutics Inc (FHTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.82 is considered Undervalued compared with the five-year average of -4.33. The fair price of Foghorn Therapeutics Inc (FHTX) is between 590.81 to 591.90 according to relative valuation methord. Compared to the current price of 5.16 USD , Foghorn Therapeutics Inc is Undervalued By 99.13%.
Relative Value
Fair Zone
590.81-591.90
Current Price：5.16
99.13%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Foghorn Therapeutics Inc (FHTX) has a current Price-to-Book (P/B) ratio of -3.27. Compared to its 3-year average P/B ratio of 174.08 , the current P/B ratio is approximately -101.88% higher. Relative to its 5-year average P/B ratio of 118.02, the current P/B ratio is about -102.77% higher. Foghorn Therapeutics Inc (FHTX) has a Forward Free Cash Flow (FCF) yield of approximately -30.28%. Compared to its 3-year average FCF yield of -32.12%, the current FCF yield is approximately -5.72% lower. Relative to its 5-year average FCF yield of -13.56% , the current FCF yield is about 123.25% lower.
P/B
Median3y
174.08
Median5y
118.02
FCF Yield
Median3y
-32.12
Median5y
-13.56
Competitors Valuation Multiple
AI Analysis for FHTX
The average P/S ratio for FHTX competitors is 4863.59, providing a benchmark for relative valuation. Foghorn Therapeutics Inc Corp (FHTX.O) exhibits a P/S ratio of 9.82, which is -99.8% above the industry average. Given its robust revenue growth of 4.42%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for FHTX
1Y
3Y
5Y
Market capitalization of FHTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of FHTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is FHTX currently overvalued or undervalued?
Foghorn Therapeutics Inc (FHTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.82 is considered Undervalued compared with the five-year average of -4.33. The fair price of Foghorn Therapeutics Inc (FHTX) is between 590.81 to 591.90 according to relative valuation methord. Compared to the current price of 5.16 USD , Foghorn Therapeutics Inc is Undervalued By 99.13% .
What is Foghorn Therapeutics Inc (FHTX) fair value?
FHTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Foghorn Therapeutics Inc (FHTX) is between 590.81 to 591.90 according to relative valuation methord.
How does FHTX's valuation metrics compare to the industry average?
The average P/S ratio for FHTX's competitors is 4863.59, providing a benchmark for relative valuation. Foghorn Therapeutics Inc Corp (FHTX) exhibits a P/S ratio of 9.82, which is -99.80% above the industry average. Given its robust revenue growth of 4.42%, this premium appears unsustainable.
What is the current P/B ratio for Foghorn Therapeutics Inc (FHTX) as of Jan 10 2026?
As of Jan 10 2026, Foghorn Therapeutics Inc (FHTX) has a P/B ratio of -3.27. This indicates that the market values FHTX at -3.27 times its book value.
What is the current FCF Yield for Foghorn Therapeutics Inc (FHTX) as of Jan 10 2026?
As of Jan 10 2026, Foghorn Therapeutics Inc (FHTX) has a FCF Yield of -30.28%. This means that for every dollar of Foghorn Therapeutics Inc’s market capitalization, the company generates -30.28 cents in free cash flow.
What is the current Forward P/E ratio for Foghorn Therapeutics Inc (FHTX) as of Jan 10 2026?
As of Jan 10 2026, Foghorn Therapeutics Inc (FHTX) has a Forward P/E ratio of -4.33. This means the market is willing to pay $-4.33 for every dollar of Foghorn Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Foghorn Therapeutics Inc (FHTX) as of Jan 10 2026?
As of Jan 10 2026, Foghorn Therapeutics Inc (FHTX) has a Forward P/S ratio of 9.82. This means the market is valuing FHTX at $9.82 for every dollar of expected revenue over the next 12 months.